Neha Patil

Ablynx

Updated on
Share on FacebookTweet on TwitterShare on LinkedIn
Traded as  ABLX
Website  www.ablynx.com
Founded  2002
Industry  Biotechnology
Headquarters  Ghent, Belgium
Ablynx wwwablynxcomassetsimagesablynxlogopng
Key people  Edwin Moses (CEO) Wim Ottevaere (CFO)
Stock price  ABLX (EBR) € 11.56 +0.04 (+0.39%)28 Feb, 3:59 PM GMT+1 - Disclaimer
Profiles
LinkedInYouTube

Ablynx


Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.

Contents

Ablynx received trends gazellen 2012 award


History

In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.

In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx. In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.

References

Ablynx Wikipedia


Similar Topics
Rattlers (film)
Chris Bennett (soccer)
Dora Mwima
Topics